Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07477639 · ClinicalTrials.gov registry record · Phase 1
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
A Phase 1 study of Multiple Sclerosis and Multiple Sclerosis (MS) Primary Progressive, sponsored by Tr1X.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT07477639: Recruiting Phase 1 study of Multiple Sclerosis and Multiple Sclerosis (MS) Primary Progressive, sponsored by Tr1X.
NCT07477639 is a Phase 1 study of Multiple Sclerosis and Multiple Sclerosis (MS) Primary Progressive that is actively recruiting participants, run by Tr1X. The registered enrollment target is 39 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07477639, a Phase 1 study of Multiple Sclerosis and Multiple Sclerosis (MS) Primary Progressive, is actively recruiting participants, sponsored by Tr1X.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS. The main questions the trial aims to answer are the following: * Is TRX319 safe when administered to patients with progressive forms of MS? * At what dose does TRX319 work the best to treat participants with primary and or secondary progressive MS? * Is pre-conditioning (with Bendamustine) needed to allow TRX319 to better treat participants with primary and/or secondary progressive MS? Participants will be asked to be on study for up 1 year and may receive up to 3 total administrations of TRX319. While on study, participants will have blood tests and other assessments (MRI scans and lumbar punctures) done to understand the safety of TRX319 and how it may benefit their multiple sclerosis.
Primary Outcome
* Number of participants with severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) * Rate of Adverse Events of Special Interest (AESIs) in participants * The safety of TRX319 determined by negative Replication Competent Lentivirus (RCL) at approximately 3-months, 6-months, and 12-months
Conditions Studied
Interventions
- DRUG Bendamustine
- BIOLOGICAL TRX319
Study Locations (2)
Kansas
- University of Kansas Medical Center - Kansas City
Missouri
- Washington University, St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2026-03 |
| Est. Completion | 2029-01 |
| Phase | Phase 1 |
What NCT07477639 shows while recruiting
NCT07477639 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (93% lower).
The record links to 5 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Bendamustine is the first listed.
NCT07477639 reports a single indexed study location in Kansas, Missouri.
Frequently Asked Questions
What is clinical trial NCT07477639 about?
NCT07477639 is a clinical study titled "Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis". The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS. The main questions the trial aims to answer are the following: * Is TRX319 safe when administered to patients with progressive ...
What is the current status of trial NCT07477639?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2026-03. Estimated completion is 2029-01.
What conditions does trial NCT07477639 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Primary Progressive Multiple Sclerosis, Multiple Sclerosis (MS) Secondary Progressive, Secondary Progressive Multiple Sclerosis (SPMS).
What interventions are being tested in trial NCT07477639?
The interventions under investigation include: Bendamustine (DRUG), TRX319 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07477639?
This trial is sponsored by Tr1X, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07477639 being conducted?
This trial has 2 study locations across Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07477639's enrollment target sits among peer trials
39 209th of 315 higher than 106 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
RECRUITING · Phase 1
-
Molecular Imaging of NET Using [C-11]MRB-PET in MS
RECRUITING · Phase 1
-
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia